H. Von Der Maase et al., Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial, ANN ONCOL, 10(12), 1999, pp. 1461-1465
Purpose: To determine the efficacy of gemcitabine and cisplatin combination
therapy in patients with advanced and/or metastatic transitional cell urot
helial carcinoma.
Patients and methods: Forty-two chemonaive patients with Karnofsky performa
nce status (KPS) greater than or equal to 70 were treated with cisplatin 35
mg/m(2) followed by gemcitabine 1000 mg/m(2) (30 min i.v. infusion) on day
s 1, 8, and 15 every twenty-eight days.
Results: Thirty-eight patients were evaluable for efficacy. Half had viscer
al disease. There were seven complete (18%) and nine partial responses (24%
), for a response rate of 42% (95% confidence interval (95% CI): 26%-59%).
Responses were independently reviewed. Median response duration was 13.5 mo
nths (95% CI: 8.5-18.1 months), median time to progressive disease 7.2 mont
hs (95% CI: 4.0-9.1 months) and median survival 12.5 months (95% CI: 8.1-18
.7 months); one-year survival was 52%. Laboratory toxicities included leuco
penia (44% grade 3; 17% grade 4), neutropenia (25% grade 3; 33% grade 4) an
d thrombocytopenia (29% grade 3; 49% grade 4). Four patients had grade 4 sy
mptomatic toxicity (three nausea and vomiting, one diarrhoea). There were n
o grade 4 infections and no toxic deaths.
Conclusions: The combination of gemcitabine and cisplatin is active in pati
ents with locally advanced and/or metastatic urothelial carcinoma. The week
ly schedule of cisplatin is considered inappropriate.